Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on ...

The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

The weight loss company will focus on its transition into a telehealth service that helps users get prescriptions for drugs ...

Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...

Pharmaceutical company Novo Nordisk is waiting on federal approval to sell its blockbuster GLP-1 weight-loss treatment as a pill.

Hims & Hers Health Inc has reiterated its 2025 revenue forecast after posting better-than-expected sales for the first ...

(Reuters) - WW International, formerly known as WeightWatchers, said it plans to file for Chapter 11 bankruptcy protection on Tuesday, as the surging popularity of obesity drugs such as Ozempic and ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

As weight-loss injectables like Ozempic skyrocket in popularity, a new offshoot trend is starting to take hold: microdosing. But experts have concerns.

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...